

景岳生物科技(股)公司

功能性益生菌領導品牌

GenMont Biotech Incorporation

The leading brand of functional probiotics

葉天佑 協理

Alvin Yeh Senior Manager



益生菌市場前景

Probiotics market outlook

- 全球益生菌市場正在快速成長

The global probiotics market is growing rapidly.

其成長的主要原因是消費者對於預防保健的意識提升

The major factor boosting the market growth is increasing concerns of consumers on preventive healthcare.



- 後疫情時代來臨，人們更積極尋求維持健康的方法

Beyond the pandemic, people have more conscious about their health and are taking proactive measures to help maintain their well-being.

隨著**COVID-19**疫情蔓延，消費者對機能性食品的長期需求增加

As the COVID-19 pandemic wears on, it increased the long-term demand for functional food/beverages and supplements in the daily behavior of consumers.



資料來源：Functional Food & Beverage 2020 Report Highlights from the Hartman Group

全球益生菌市場快速發展

Global probiotics market is growing rapidly

全球市場分析報告顯示，**預計2026年全球益生菌市場約為911億美元**。



The global market analysis report shows that the global probiotic market is expected to be about 91.1 billion US dollars in 2026.

全球益生菌市場應用

Global probiotics market by product application

***市場分布 MARKET SHARE**

- 功能性食品 Functional food
- 保健食品與藥品 Health food and medicine
- 益生菌原料 Probiotics raw material



資料來源：

https://www.reportlinker.com/p05129364/Probiotics-Market-by-Application-Dietary-Supplements-Animal-Feed-Source-Form-End-User-And-Region-Forecast-to.html?utm_source=GNW;
<https://www.researchandmarkets.com/reports/5370159/global-probiotics-market-by-application>




2022年度研究成果介紹

The Annual Research Presentation 2022




167項研發專利

Patents over the world



49篇文獻發表

Published Papers



後生元/熱滅活乳酸桿菌 功效研究

Postbiotics/Heat-Inactivated *Lactobacillus* Efficacy studies

>對宿主健康有益的無生命微生物和/或其成分的製劑

Preparation of inanimate microorganisms and/or their components that confers a health benefit on the host

>國際益生菌和益生元科學協會(ISAPP)關於後生元的定義和範圍的共識聲明

Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics

- 熱滅活羅伊氏乳桿菌 GMNL-263 經由活化IGF1R路徑來緩解高血糖引起的心臟損傷
Hyperglycemia-Induced Cardiac Damage Is Alleviated by Heat-Inactivated *Lactobacillus reuteri* GMNL-263 via Activation of the IGF1R Survival Pathway. Probiotics Antimicrob Proteins. 2021 Aug;13(4):1044-1053.
- 熱滅活羅伊氏乳桿菌 GMNL-263藉由抑制TLR-4路徑來改善糖尿病引起的心肌病變
Diabetes-induced cardiomyopathy is ameliorated by heat-killed *Lactobacillus reuteri* GMNL-263 in diabetic rats via the repression of the toll-like receptor 4 pathway. Eur J Nutr. 2021 Sep;60(6):3211-3223.
- 熱滅活乳酸桿菌製劑促進實驗性的皮膚創傷癒合
Heat-Killed Lactobacilli Preparations Promote Healing in the Experimental Cutaneous Wounds. Cells 2021 Nov 22;10(11):3264.
- 熱滅活副乾酪乳桿菌GMNL-653經由恢復卵巢摘除小鼠腸道菌相紊亂情形，來發揮抗骨質疏鬆作用
Heat-Killed *Lactocaseibacillus paracasei* GMNL-653 Exerts Antiosteoporotic Effects by Restoring the Gut Microbiota Dysbiosis in Ovariectomized Mice. Front. Nutr. 2022 Feb 4;9:804210.



財務狀況 Financial status

※母公司財報-景岳生技 Separate Financial Statements-GenMont

單位：千元 In Thousands of New Taiwan Dollars	108年母公司財報 (Year 2019 Single)	109年母公司財報 (Year 2020 Single)	110年母公司財報 (Year 2021 Single)
營業收入NET REVENUE	346,244	325,191	427,929
營業毛利GROSS PROFIT	229,701	215,390	299,326
營業費用OPERATING EXPENSES	(148,838)	(137,605)	(150,140)
營業利益INCOME(LOSS) FROM OPERATIONS	80,863	77,785	149,186
營業外損益NON- OPERATING INCOME AND EXPENSES	(5,107)	(269)	(6,231)
稅前淨利INCOME(LOSS) BEFORE INCOME TAX	75,756	77,516	142,955
稅後淨利NET INCOME(LOSS)	57,451	60,884	113,132



財務狀況 Financial status

※合併財報 Consolidated Financial Statements

單位：千元 In Thousands of New Taiwan Dollars	109年合併 (Year 2020 Consolidated)	110年合併 (Year 2021 Consolidated)	111年前二季合併 (Year 2022 H1 Consolidated)
營業收入NET REVENUE	325,191	427,929	186,445
營業毛利GROSS PROFIT	215,390	299,326	130,639
營業費用OPERATING EXPENSES	(144,376)	(174,287)	(90,445)
營業利益INCOME(LOSS) FROM OPERATIONS	71,014	125,039	40,194
營業外損益NON-OPERATING INCOME AND EXPENSES	5,833	14,385	1,316
稅前淨利INCOME(LOSS) BEFORE INCOME TAX	76,847	139,424	41,510
稅後淨利NET INCOME(LOSS)	60,215	109,601	31,039
停業單位損益Income (Loss)from Discontinued Operations	0	0	0
本期淨利NET INCOME(LOSS)	60,215	109,601	31,039



風險評估 Risk Assessment

生技領域方面財務風險Financial risk in the biotech sector

- 研發期間長 Long R & D period
 - 獲利回收晚 Late profit recovery
- ➡ 可能因此導致資金不足 Which may lead to insufficient funds

益生菌市場持續成長Probiotics market continues to grow

根據Precedence Research預估，2021年至2030年全球益生菌市場年平均複合成長率(CAGR)將可達8.7%，至2030年時其規模可達1,339億美元；其中食品飲料市場的規模最大(達75%以上)，動物飼料則成長最快速。目前市場以亞太地區為主，市場占比超過七成。

According to Precedence Research estimates, the global probiotics market will reach an average annual compound growth rate (CAGR) of 8.7% from 2021 to 2030, and its scale will reach US\$133.9 billion by 2030; the food and beverage market is the largest (up to 75% or more), animal feed is the fastest growing. At present, the market is dominated by the Asia-Pacific region, accounting for more than 70% of the market.





Thanks For Your Attention

Q & A

